February 26 Market Update: Key Stocks and Corporate Developments

SBI Life Insurance Declares Interim Dividend for FY26​

SBI Life Insurance has announced an interim dividend of ₹2.70 per equity share for the financial year 2025 to 26. Shareholders whose names appear on the record date of March 6, 2026 will be eligible to receive the payout.

The company stated that the dividend will be credited or dispatched on or before March 27, 2026.

Tata Capital Housing Finance Approves ₹650.02 Crore Rights Issue​

Tata Capital Ltd said its wholly owned subsidiary, Tata Capital Housing Finance Ltd, has approved a rights issue of equity shares worth ₹650.02 crore to its parent company.

The issue comprises equity shares with a face value of ₹10 each and will be executed in one or more tranches, strengthening the subsidiary’s capital base.

Government to Sell 2 Percent Stake in IRFC; Raises $400 Million ECB​

Indian Railway Finance Corporation Ltd stated that the government will not exercise the oversubscription option in its ongoing Offer for Sale. The Centre is divesting a 2 percent equity stake at a floor price of ₹104 per share.

The OFS opened for non retail investors on February 25 and will open for retail investors on February 26. The government had earlier indicated a possible additional 2 percent green shoe option, which could have taken the total stake sale to 4 percent.

Separately, IRFC has raised a $400 million equivalent Japanese Yen denominated external commercial borrowing from SMBC and MUFG’s GIFT City branches. The funds will be used for railway linked projects.

Reliance Enterprise Intelligence Becomes Step Down Subsidiary of RIL​

Reliance Industries Ltd said that Reliance Enterprise Intelligence Ltd has become its step down subsidiary following the allotment of 85.32 crore shares.

Of the total allotment, 70 percent was issued to Reliance Intelligence Ltd, while 30 percent was allotted to Facebook Overseas, Inc., a wholly owned arm of Meta Platforms, Inc.

Lupin Under GST Inspection in Maharashtra​

Lupin informed that the Maharashtra GST Department has initiated an inspection and search at its office.

The proceedings relate to documents concerning GST payments and input tax credit claims. The company clarified that it is cooperating with authorities and that the inspection has no impact on its financials or operations.

Zydus Lifesciences Receives DCGI Nod for Semaglutide Injections​

Zydus Lifesciences has received approval from the DCGI to manufacture and market semaglutide injections for the treatment of Type 2 diabetes and obesity.

The drug will be launched under three brand names, SEMAGLYN™, MASHEMA™ and ALTERMET™. The company said the product will feature an indigenously developed adjustable, reusable single pen delivery system.

KFin Technologies JV Strengthens Leadership​

KFin Technologies Ltd said its joint venture, MFC Technologies, has appointed Rajesh Krishnamoorthy as Chief Executive Officer and Supratim Bandyopadhyay as Non Executive Chairman of the Board.

The appointments are aimed at strengthening independent governance as MF Central transitions into a professionally managed standalone entity serving India’s mutual fund ecosystem.

Dixon Technologies Sells 3.8 Percent Stake in Aditya InfoTech​

In a block deal, Dixon Technologies sold a 3.8 percent stake in Aditya InfoTech for ₹661 crore.

Motilal Oswal Mutual Fund and Kotak Mahindra Mutual Fund acquired shares worth ₹180 crore each. Other buyers included Axis Mutual Fund, HDFC Life Insurance and 360 One Mutual Fund.

Emmvee Photovoltaic Says US Duties Will Not Impact Operations​

Emmvee Photovoltaic Power Ltd said recent US countervailing duties on solar imports from India will not affect its operations.

The company stated that its integrated solar cell and module manufacturing is largely aligned with domestic demand and that it remains focused on India’s renewable energy market and expanding high efficiency manufacturing capacity.

Sanofi India Recommends ₹48 Final Dividend; Q4 Profit Jumps 50 Percent​

Sanofi India Ltd has recommended a final dividend of ₹48 per share for FY2025, taking the total dividend payout to ₹123 per share, including the ₹75 interim dividend.

For the fourth quarter, revenue rose 47 percent year on year to ₹251 crore, supported by 23 percent growth in domestic sales and a sharp increase in exports. Profit after tax climbed 50 percent to ₹66.5 crore.

Shaily Engineering Plastics Secures ₹423 Crore Pen Injector Deal​

Shaily Engineering Plastics has secured a manufacturing and commercial supply agreement worth ₹423 crore from a large domestic pharmaceutical company.

The four year contract covers pen injectors, with the customer’s identity withheld due to confidentiality obligations.